Robert E. Gagnon
Net Worth
Last updated:
What is Robert E. Gagnon net worth?
The estimated net worth of Mr. Robert E. Gagnon is at least $3,206,205 as of 19 Dec 2024. He owns shares worth $273,403 as insider, has earned $327,922 from insider trading and has received compensation worth at least $2,604,880 in Verastem, Inc..
What is the salary of Robert E. Gagnon?
Mr. Robert E. Gagnon salary is $651,220 per year as Chief Bus. & Financial Officer in Verastem, Inc..
How old is Robert E. Gagnon?
Mr. Robert E. Gagnon is 51 years old, born in 1974.
What stocks does Robert E. Gagnon currently own?
As insider, Mr. Robert E. Gagnon owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Verastem, Inc. (VSTM) | Chief Bus. & Financial Officer | 34,477 | $7.93 | $273,403 |
What does Verastem, Inc. do?
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Robert E. Gagnon insider trading
Verastem, Inc.
Mr. Robert E. Gagnon has made 25 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 130 units of VSTM stock worth $568 on 19 Dec 2024.
The largest trade he's ever made was exercising 19,612 units of VSTM stock on 3 Jan 2022. As of 19 Dec 2024 he still owns at least 34,477 units of VSTM stock.
Verastem key executives
Verastem, Inc. executives and other stock owners filed with the SEC:
- Mr. Brian M. Stuglik BPHARM, R.Ph., RPh (66) Chief Executive Officer & Director
- Mr. Daniel W. Paterson (64) Chief Operating Officer & Pres
- Mr. Robert E. Gagnon (51) Chief Bus. & Financial Officer